Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05986682 · OUTCOME

Treatment Characteristics: Dosing Patterns - Delays in Treatment With BLENREP Therapy

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

Number of participants for whom BLENREP dosing was delayed during treatment as categorized by reason.

Groups in this outcome

Multiple Myeloma/Blenrep Participants

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Multiple Myeloma/Blenrep Participants30

Reported measurements

Delay for any reason
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants27Not reportedNot reportedNot reportedNot reported
Delay for Corneal AE
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants27Not reportedNot reportedNot reportedNot reported
Delay for Other Ocular Toxicity
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants2Not reportedNot reportedNot reportedNot reported
Delay for Hematologic Toxicity
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants3Not reportedNot reportedNot reportedNot reported
Delay for Physician/Patient Choice
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants2Not reportedNot reportedNot reportedNot reported
Delay for any other reason
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants10Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        27
    title
    Delay for any reason
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        27
    title
    Delay for Corneal AE
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Delay for Other Ocular Toxicity
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Delay for Hematologic Toxicity
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Delay for Physician/Patient Choice
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    Delay for any other reason
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
Number of participants for whom BLENREP dosing was delayed during treatment as categorized by reason.
groups
  1. description
    Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023.
    id
    OG000
    title
    Multiple Myeloma/Blenrep Participants
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
title
Treatment Characteristics: Dosing Patterns - Delays in Treatment With BLENREP Therapy
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice